Information Provided By: 
Fly News Breaks for April 21, 2017
TXMD
Apr 21, 2017 | 12:24 EDT
Stifel analyst Annabel Samimy says TherapeuticsMD's recently disclosed a deficiency letter from the FDA has created confusion in the market. A Complete Response Letter is the likely next step, but TX004HR "presents a clear clinical improvement" to current available options and remains approvable, Samimy tells investors in a research note. The analyst expects clarity on the situation over the next two weeks and keeps a Buy rating on TherapeuticsMD with a $20 price target. The stock in midday trading is down 22c to $4.69.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
